Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
Perspective Therapeutics (NYSE AMERICAN: CATX) will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg, Germany, from October 19-23, 2024. The company will showcase several presentations, including:
1. Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, targeting fibroblast activation protein-alpha (FAP).
2. Impact of molar activity on [203Pb]Pb-VMT-α-NET biodistribution in neuroendocrine tumor xenografts.
3. Interim results of 212Pb-VMT-α-NET Targeted Alpha Therapy in metastatic gastro-entero-pancreatic neuroendocrine tumors.
4. Image-guided evaluation of 212Pb-VMT-α-NET in metastatic neuroendocrine tumors.
The presentations will include updated analyses from investigator-led clinical research and preclinical studies, focusing on novel radiopharmaceutical treatments for various cancers.
Perspective Therapeutics (NYSE AMERICAN: CATX) presenterà dati preclinici aggiornati su PSV359 durante il 37° Congresso Annuale dell'Associazione Europea di Medicina Nucleare (EANM) che si terrà ad Amburgo, Germania, dal 19 al 23 ottobre 2024. L'azienda mostrerà diverse presentazioni, tra cui:
1. Valutazione preclinica e prima imaging nell'uomo di [203/212Pb]Pb-PSV359, mirato alla proteina di attivazione dei fibroblasti-alfa (FAP).
2. Impatto dell'attività molare sulla biodistribuzione di [203Pb]Pb-VMT-α-NET in xenotrapianti di tumori neuroendocrini.
3. Risultati intermedi della Terapia Alpha Mirata con 212Pb-VMT-α-NET nei tumori neuroendocrini gastro-entero-pancreatici metastatizzati.
4. Valutazione guidata da immagini di 212Pb-VMT-α-NET in tumori neuroendocrini metastatici.
Le presentazioni includeranno analisi aggiornate da ricerche cliniche guidate da investigatori e studi preclinici, focalizzandosi su nuovi trattamenti radioterapici per vari tipi di cancro.
Perspective Therapeutics (NYSE AMERICAN: CATX) presentará nuevos datos preclínicos sobre PSV359 en el 37º Congreso Anual de la Asociación Europea de Medicina Nuclear (EANM) que se celebrará en Hamburgo, Alemania, del 19 al 23 de octubre de 2024. La compañía mostrará varias presentaciones, incluyendo:
1. Evaluación preclínica e imágenes de primera línea en humanos de [203/212Pb]Pb-PSV359, dirigido a la proteína de activación de fibroblastos-alfa (FAP).
2. Impacto de la actividad molar en la biodistribución de [203Pb]Pb-VMT-α-NET en xenoinjertos de tumores neuroendocrinos.
3. Resultados intermedios de la terapia Alpha Dirigida con 212Pb-VMT-α-NET en tumores neuroendocrinos gastro-entero-pancreáticos metastásicos.
4. Evaluación guiada por imágenes de 212Pb-VMT-α-NET en tumores neuroendocrinos metastásicos.
Las presentaciones incluirán análisis actualizados de investigaciones clínicas dirigidas por investigadores y estudios preclínicos, centrándose en nuevos tratamientos radioterapéuticos para varios tipos de cáncer.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 2024년 10월 19일부터 23일까지 독일 함부르크에서 열리는 유럽 핵의학회 제37회 연례 총회에서 PSV359에 대한 업데이트된 전임상 데이터를 발표할 예정입니다. 회사는 다음과 같은 여러 프레젠테이션을 선보일 것입니다:
1. 섬유아세포 활성화 단백질 알파(FAP)를 타겟으로 하는 [203/212Pb]Pb-PSV359의 전임상 평가 및 첫 번째 인간 이미지.
2. 신경내분비 종양의 이식에서 [203Pb]Pb-VMT-α-NET의 생체 분포에 대한 몰 농도의 영향.
3. 전이성 위장관 신경내분비 종양에 대한 212Pb-VMT-α-NET 표적 알파 요법의 중간 결과.
4. 전이성 신경내분비 종양에서 212Pb-VMT-α-NET의 이미지 유도 평가.
발표에는 연구자 주도 임상 연구 및 전임상 연구의 업데이트된 분석이 포함되어 있으며, 다양한 암에 대한 새로운 방사성 약품 치료를 중점적으로 다룰 것입니다.
Perspective Therapeutics (NYSE AMERICAN: CATX) présentera des données précliniques mises à jour sur PSV359 lors du 37ème Congrès Annuel de l'Association Européenne de Médecine Nucléaire (EANM) à Hambourg, en Allemagne, du 19 au 23 octobre 2024. La société mettra en avant plusieurs présentations, y compris :
1. Évaluation préclinique et première imagerie chez l'homme de [203/212Pb]Pb-PSV359, ciblant la protéine d'activation des fibroblastes-alpha (FAP).
2. Impact de l'activité molaire sur la biodistribution de [203Pb]Pb-VMT-α-NET dans des xénogreffes de tumeurs neuroendocrines.
3. Résultats intermédiaires de la Thérapie Alpha Ciblée avec 212Pb-VMT-α-NET dans les tumeurs neuroendocrines gastro-entéro-pancréatiques métastatiques.
4. Évaluation guidée par l'image de 212Pb-VMT-α-NET dans les tumeurs neuroendocrines métastatiques.
Les présentations incluront des analyses mises à jour provenant de recherches cliniques menées par des investigateurs et d'études précliniques, en se concentrant sur de nouveaux traitements radiopharmaceutiques pour divers cancers.
Perspective Therapeutics (NYSE AMERICAN: CATX) wird aktualisierte präklinische Daten zu PSV359 auf dem 37. jährlichen Kongress der Europäischen Gesellschaft für Nuklearmedizin (EANM) in Hamburg, Deutschland, vom 19. bis 23. Oktober 2024 präsentieren. Das Unternehmen wird mehrere Präsentationen vorstellen, darunter:
1. Präklinische Bewertung und erste Bildgebung beim Menschen mit [203/212Pb]Pb-PSV359, das auf das Fibroblasten-Aktivierungsprotein-alpha (FAP) abzielt.
2. Einfluss der molaren Aktivität auf die Biodistribution von [203Pb]Pb-VMT-α-NET in neuroendokrinen Tumor-Xenografts.
3. Zwischenbilanz der 212Pb-VMT-α-NET zielgerichteten Alpha-Therapie bei metastasierten gastroenteropankreatischen neuroendokrinen Tumoren.
4. Bildgeführte Auswertung von 212Pb-VMT-α-NET bei metastasierten neuroendokrinen Tumoren.
Die Präsentationen beinhalten aktualisierte Analysen aus von Forschern geleiteten klinischen Studien und präklinischen Studien, die sich auf neuartige radiopharmazeutische Behandlungen für verschiedene Krebsarten konzentrieren.
- None.
- None.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company’s other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM.
Descriptions of these presentations are provided in the table below. The abstract book is available online at https://link.springer.com/article/10.1007/s00259-024-06838-z.
| Presenter | Abstract Title | Presentation Details |
| Perspective Update on PSV-359 | ||
| Brianna S. Cagle, PhD | Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, a novel cyclic peptide targeting fibroblast activation protein-alpha (FAP) | Abstract ID: OP-473 Session Type: Oral Presentation Session: Featured Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: FAP Therapies: Mechanisms and Response Session Date: Monday, October 21, 2024 Session Time: 6:05 PM |
| Perspective Update on VMT-α-NET | ||
| D. Liu, PhD | Impact of molar activity on [203Pb]Pb-VMT-α-NET biodistribution profile in mice bearing neuroendocrine tumor xenograft | Abstract ID: OP-020 Session Type: Oral Presentation Session: Featured Session: Translational Molecular Imaging & Therapy Committee + Radiopharmaceutical Sciences Committee: Tracer (Pharmaco) Kinetics Session Date: Sunday, October 20, 2024 Session Time: 8:00 AM |
| Investigator-Led Research on VMT-α-NET | ||
| Dharmender Malik | Interim results of 212Pb-VMT-α-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First In-human Clinical Results on Safety and Efficacy | Presentation #: OP-256 Session #: 611 Session Title: Theranostics Track - TROP Session: Oncology & Theranostics Committee: Neuroendocrine Therapy Session Date: Sunday, October 20, 2024 Session Time: 4:45-6:15 PM Session Hall: Hall Y1-Y3 |
| Dharmender Malik | Image guided evaluation of 212Pb-VMT-α-NET in metastatic Neuroendocrine tumors: Bio distribution and Dosimetry | ePoster #: EP-0929 Session #: EP-58 |
| Investigator-Led Preclinical Research | ||
| Dongyoul Lee | Evaluation and Design of New Chelators using Density Functional Theory Modeling: Implications for Improved Performance of 203Pb/212Pb-based Theranostic for Cancers | ePoster #: EP-0993 Session #: EP-62 |
| Jung Woo Byun | Development of 203Pb Labeled SSTR-Targeting Peptides as Surrogates for 212Pb Labeled Radiopharmaceuticals | ePoster #: EP-0102 Session #: EP-04 |
PSV359
The Company will present updated preclinical data on PSV359, a novel cyclic peptide targeting fibroblast activation protein-alpha (FAP) and a molecular linker to a lead-specific chelator.
An oral presentation combining first-in-human SPECT/CT images generated by an independent investigator using [203Pb]Pb-PSV359, along with updated analysis of preclinical studies of [212Pb]Pb-PSV359 conducted by the Company, will be presented.
[212Pb]VMT-α-NET for the Treatment of Neuroendocrine Tumors (NETs)
The Company has been informed that two updated analyses based on investigator-led clinical research of [212Pb]VMT-α-NET in India have been accepted for presentation by the EANM conference. The investigator enrolled adult patients with histologically confirmed gastroenteropancreatic neuroendocrine tumors (“GEP-NETs”) and metastatic medullary thyroid carcinomas. The most recent prior public update of this patient series was during the Society of Nuclear Medicine & Molecular Imaging ("SNMMI") Annual Meeting in June 2024.
- The investigator informed the Company that an oral presentation will be provided on the GEP-NET patients as of a later cut-off date than the cut-off date for the SNMMI conference. The analysis presented at SNMMI was based on 10 GEP-NET patients plus 3 patients with other SSTR2+ tumors as of a data cutoff date of May 31, 2024.
- An ePoster to be presented at the conference will focus on the biodistribution and image-guided dosimetric estimates of the [212Pb]VMT-α-NET. Dosimetry data presented during SNMMI was based on two patients.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; expectations regarding the timing and advancement of the Company's clinical and preclinical programs; the FAP binding affinity and specificity of [203/212Pb]Pb-PSV-359; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides; the opportunity to personalize treatment and optimize patient outcomes using the Company's complementary imaging diagnostics that incorporate the same targeting peptides; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat them to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; expectations regarding the potential market opportunities for the Company's product candidates; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
FAQ
What will Perspective Therapeutics present at the EANM Congress 2024?
When and where is the 37th Annual Congress of the European Association of Nuclear Medicine taking place?
What are the key presentations by Perspective Therapeutics (CATX) at EANM 2024?
What is the focus of the investigator-led research on VMT-α-NET being presented at EANM 2024?
How does the EANM 2024 presentation on VMT-α-NET compare to previous updates by Perspective Therapeutics (CATX)?
